Skip to content

Helping patients reclaim a life of possibility

Menu

About us
Contact us

Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month
  
  MPE Masterclass
  
  Scholarship programme
  
  Care Connect Programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month
  
  MPE Masterclass
  
  Scholarship programme
  
  Care Connect Programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Day: September 22, 2026

EMA committee recommends melflufen label expansion to third-line myeloma treatment

Access, Myeloma22 September 2026

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026

Contact
About us
Privacy policy
Terms and conditions
Cookies Policy

About MPE
Contact us
Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
Educational Resources
News
European Myeloma Day

PopUp

Company
This field is for validation purposes and should be left unchanged.
I am a*
- Patient
- Patient advocate
- Caregiver
- Doctor